Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Industry, Research and Development, Taxation and Finance
|
Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
|
Policies or Program
|
|
Economic Development, Health, Industry, Intellectual Property, Research and Development
|
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
|
Policies or Program
|
|
Health, Industry, Research and Development, Science and Technology
|
Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
|
Regulation, Policies or Program
|
|
Economic Development, Health, Research and Development
|
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
|
Policies or Program, Grant, Contribution or Other Financial Benefit
|
|
Economic Development, Health, International Trade, Research and Development, Taxation and Finance
|
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
|
Policies or Program
|
|
Federal-Provincial Relations, Health, Industry, International Development, Research and Development
|
Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
|
Regulation, Policies or Program
|
|
Aboriginal Affairs, Government Procurement, Health
|
Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
|
Policies or Program
|
|
Intellectual Property, International Trade, Research and Development, Science and Technology
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Regulation
|
|
Health, Industry, Intellectual Property, Research and Development, Science and Technology
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Policies or Program, Regulation
|
|
Health, Industry, Research and Development
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
|
Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property, Research and Development
|
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
|
Policies or Program, Regulation
|
|
Budget, Economic Development, Federal-Provincial Relations, Foreign Affairs, Government Procurement, Health, Industry, International Trade, Research and Development
|
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
|
Regulation, Policies or Program
|
|
Government Procurement, Health, Research and Development
|
Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
|
Policies or Program
|
|
Industry, International Development, Taxation and Finance
|
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
|
Policies or Program
|
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.
Gaby Bourbara, President
Address:
1004 Middlegate Road, Suite 5000
Mississauga, ON L4Y 1M4
Canada
Telephone number:
800-565-5877
AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Please note that registrations and registration updates with effective dates of January 19, 2026, or after will be subject to the new significant part of duties threshold. For more information, please consult our interpretation bulletin.